Dallas Fort Worth Injury Lawyer Blog
The Supreme Court forcefully rejected calls for limiting consumer lawsuits against drug makers, upholding a $6.7 million jury award to a musician who lost her arm to gangrene following an injection.
The decision is the second this term to reject business groups’ arguments that federal regulation effectively pre-empts consumer complaints under state law.
Diana Levine of Vermont once played the guitar and piano professionally. Her right arm was amputated after she was injected with Phenergan, an anti-nausea medicine made by Wyeth Pharmaceuticals, using a method that brings rapid relief, but with grievous risks if improperly administered.
In a 6-3 decision, the court turned away Wyeth’s claim that federal approval of Phenergan and its warning label should have shielded the company from lawsuits like Levine’s.
Levine’s lawsuit said she was not sufficiently warned of the risks of using Phenergan. But according to Bert Rein, the lawyer who represents Wyeth, said the company’s label complied with federal law.
“Wyeth’s labeling of Phenergan provided clear instructions and warnings about its use, including clear warnings about the very risk at issue in this case,” Rein said.
The central issue in this case was the absence of language in the federal law setting out regulation of prescription drugs that forecloses consumer complaints in state courts. Congress has included such language in other areas.
“Unless Congress has spoken directly to the question, the court this term has said it is not going to favor broader arguments for pre-emption,” said David Frederick, who represented Levine and the cigarette smokers who won an earlier ruling this term allowing their lawsuits against tobacco companies to proceed.
The Levine case drew a lot of attention because the administration and Wyeth contended that, although the federal Food, Drug and Cosmetic Act lacks a similar provision, drug manufacturers also are protected from most suits over federally approved drugs.
A Vermont jury agreed with Levine’s claim that Wyeth failed to provide a strong and clear warning about the risks of quickly injecting the drug into a vein, a method called “IV push.” Gangrene is likely if the injection accidentally hits an artery — precisely what happened to Levine.
The company appealed and, backed by the Bush administration, argued that once a drug’s warning label gets approval from the Food and Drug Administration, the label cannot be changed without further FDA approval and consumers cannot pursue state law claims that they were harmed.
Justice John Paul Stevens, writing the majority opinion, said Wyeth could “unilaterally strengthen its warning,” especially after it learned of at least 20 incidents before Levine’s injury in which an injection led to gangrene and amputation.
Stevens said he was persuaded that until a recent change by the FDA, the agency “traditionally regarded state law as a complementary form of drug regulation” because it monitors 11,000 drugs.
Stevens said there could be circumstances where consumer lawsuits would not be allowed, including if the FDA had considered and rejected a stronger warning label.
But that was not the case with Phenergan, he said. “As we have discussed, the FDA did not consider and reject a stronger warning against IV-push injection of Phenergan,” Stevens said.
The case is Wyeth v. Levine, 06-1249.
If you or a family member has been injured because of the fault of someone else; by negligence, personal injury, slip and fall, car accident, medical malpractice, trucking accident, drunk driving, bad product, toxic injury etc then please contact the Fort Worth Texas Personal Injury Attorney Dr. Shezad Malik. For a no obligation, free case analysis, please call 817-255-4001 or Contact Me Online.